New York, November 05, 2024 - PRISM MarketView - Quoin Pharmaceuticals (Nasdaq: QNRX) has initiated clinical testing of its lead product, QRX003, in a pediatric patient with Netherton Syndrome (NS) at Children’s Health Ireland. This trial marks the first time QRX003 is being evaluated in a young child, representing a significant step in expanding the patient base and data for this potential treatment. A second site in Spain is set to open soon, with plans to assess up to three additional pediatric NS patients.
The prognosis for children with NS can be severe, with a high risk of fatal complications within the first years of life. Currently, no approved therapeutics are available, and patients often rely on off-label medications to manage symptoms.
“We are pleased to announce this latest initiative for Quoin as we strive to generate the broadest and most diverse data set possible for QRX003 in Netherton Syndrome patients. Furthermore, we are delighted that Professor Irvine, one of the world’s leading researchers in this disease, has agreed to perform this assessment of QRX003. Currently, we are testing patients aged 14 years and up in our two ongoing clinical studies and we hope that data generated by Professor Irvine will facilitate lowering the eligibility age further.”
Quoin CEO Dr. Michael Myers
QRX003 study results to date have been promising, with all evaluable subjects demonstrating improvement across multiple endpoints and no treatment-related adverse events recorded.
This milestone aligns with Quoin’s focus on advancing QRX003 toward regulatory approval. By including younger patients in testing, Quoin aims to support broader eligibility criteria, positioning QRX003 as a comprehensive treatment option for both adult and pediatric NS patients worldwide.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities